Mark Pegram, MD
Enriched profileSusy Yuan-Huey Hung Endowed Professor of Medical Oncology; Associate Director of Clinical Research, Stanford Comprehensive Cancer Institute; Associate Dean for Clinical Research Quality, Stanford School of Medicine; Medical Director, Stanford Clinical Translational Research Unit · Stanford University School of Medicine
Mark Pegram is Susy Yuan-Huey Hung Endowed Professor of Medical Oncology; Associate Director of Clinical Research, Stanford Comprehensive Cancer Institute; Associate Dean for Clinical Research Quality, Stanford School of Medicine; Medical Director, Stanford Clinical Translational Research Unit at Stanford University School of Medicine. OpenAlex indexes 421 publications with 41,838 citations (h-index 67); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 13 Oct 2026
Mark D. Pegram, MD, is Susy Yuan-Huey Hung Endowed Professor of Medical Oncology at Stanford University School of Medicine, Department of Medicine - Oncology (Stanford Women's Cancer Center / Stanford Comprehensive Cancer Institute). The public record shows 421 publications with 41,838 citations (h-index 67), centered on HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Cancer Treatment and Pharmacology. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 25 companies, 1 NIH-funded awards (2016–2020).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: HER2/EGFR in Cancer Research
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 25 companies
Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 15 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 169.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer
Sponsor: Stanford University
- T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
Sponsor: Jonsson Comprehensive Cancer Center
Industry payments
Updated 13 Oct 2026
25 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202519 payments$19,170openpaymentsdata.cms.gov ↗
- Stemline Therapeutics Inc.Program year20259 payments
- PFIZER INC.Program year20253 payments
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Aromatase Inhibitor60%Anastrozole100%Part D<11 patientsEstrogen Agonist/Antagonist40%Tamoxifen Citrate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 13 Oct 2026
1 NIH research award on record, funded 2016–2020 per NIH RePORTER. The latest:
Congress activity
Updated 13 Oct 2026
122 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract LB169: Establishment of patient-derived organoid (PDO) from single cell-originated core-needle biopsied (CNB) samples of breast cancer
AACR Annual Meeting
AACR2025Co-authorLate-breaking - Predictors of overall survival in patients with brain metastases from HER2+ breast cancer.
ASCO Annual Meeting
ASCO2025Co-author - Prospective decision impact study of the Breast Cancer Index: Results from the BCI Registry study.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 13 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.
Journal of clinical oncology
Clinical Trial2026 - Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.
Clinical cancer research
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer3,794 citations2012
- 04
- 05
Network
Updated 13 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 13 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/mark-pegram-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/p/DQHaOEYjsea
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗ - LinkedIn
linkedin.com/posts/lieszl_mark-pegram-md-reviews-utility-of-breast-activity-6950965806847463425-gbAY
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Other
mashupmd.com/podcast-mark-pegram-md-stanfordhealth-stanfordcanc
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mashupmd.com ↗ - YouTube
oncologytube.com/mark-pegram-md-stanford-stanfordcancer-miamibreast22-breast22-new-frontiers-in-breast-cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncologytube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- Editorial board member
Breast Cancer Research and Treatment (Springer Nature)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →link.springer.com ↗ - First Director
Breast Cancer Oncology Program, Stanford Women's Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →stanfordhealthcare.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- Keynote Lecture
American Radium Society 94th Annual Meeting
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →giantsofcancercare.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →giantsofcancercare.com ↗
Secondary affiliations
appointments beyond the home institution- Member
Bio-X, Stanford University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biox.stanford.edu ↗ - Member
Stanford Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗ - Scientific Advisory Board member
Beyond Cancer (appointed alongside Frederick M. Dirbas, MD, per sponsored research agreement with Stanford)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →beyondcancer.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncologytube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mashupmd.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Heidenreich, MD
Stanford University School of Medicine
Alan Schatzberg, MD
Stanford University School of Medicine
Euan Ashley, MD
Stanford University School of Medicine
Vibeke Strand, MD
Stanford University School of Medicine
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Hope Rugo, MD
City of Hope
Dennis Slamon, MD
University of California, Los Angeles